2023 was an exciting year for #cardiometabolic medicine. Here are some of the Top Cardiometabolic Stories of 2023.
#obesity #diabetes #NAFLD #MASLD #CVD #prediabetes #menopause
#obesity #diabetes #NAFLD #MASLD #CVD #prediabetes #menopause
Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight loss of almost 15% with similar side effects to injectable GLP-1 receptor agonists.
nejm.org
nejm.org
Number 9 Top Cardiometabolic Story of 2023:
Advances in how to identify high-risk patients with #MASLD in endocrinology clinics. @theaace
endocrinepractice.org
Advances in how to identify high-risk patients with #MASLD in endocrinology clinics. @theaace
endocrinepractice.org
Number 8 Top Cardiometabolic Story of 2023:
Hormonal changes in #menopause play a role in the development of #MASLD.
healio.com
Hormonal changes in #menopause play a role in the development of #MASLD.
healio.com
Number 7 Top Cardiometabolic Story of 2023:
The American Diabetes Association now advises universal screening of people with type 2 #diabetes and prediabetes for #MASLD. @AmDiabetesAssn @Medscape @MiriamETucker
medscape.com
The American Diabetes Association now advises universal screening of people with type 2 #diabetes and prediabetes for #MASLD. @AmDiabetesAssn @Medscape @MiriamETucker
medscape.com
Number 6 Top Cardiometabolic Story of 2023:
Growth hormone treatment reduces liver steatosis, inflammation and fibrosis making it a potential therapeutic option for #MASLD and #MASH.
healio.com
Growth hormone treatment reduces liver steatosis, inflammation and fibrosis making it a potential therapeutic option for #MASLD and #MASH.
healio.com
Number 5 Top Cardiometabolic Story of 2023:
@TheAACE 2023 Type 2 Diabetes Algorithm presents both complications-centric and glucose-centric management pathways.
endocrinepractice.org
@TheAACE 2023 Type 2 Diabetes Algorithm presents both complications-centric and glucose-centric management pathways.
endocrinepractice.org
Number 4 Top Cardiometabolic Story of 2023:
International consensus renamed non-alcoholic fatty liver disease #NAFLD to metabolic dysfunction-associated steatotic liver disease #MASLD #MASH @marurinella @JVLazarus @AASLDtweets @NoureddinMD @juanpabloarab
aasld.org
International consensus renamed non-alcoholic fatty liver disease #NAFLD to metabolic dysfunction-associated steatotic liver disease #MASLD #MASH @marurinella @JVLazarus @AASLDtweets @NoureddinMD @juanpabloarab
aasld.org
Number 3 Top Cardiometabolic Story of 2023:
The SELECT trial found that #semaglutide reduced the risk of CV death by 20% in patients with #obesity without diabetes.
nejm.org
The SELECT trial found that #semaglutide reduced the risk of CV death by 20% in patients with #obesity without diabetes.
nejm.org
Number 2 Top Cardiometabolic Story of 2023:
FDA approves #Zepbound #tirzepatide for weight loss. @CBSEveningNews #Mounjaro #obesity #weightlossjourney #weightloss
cbsnews.com
FDA approves #Zepbound #tirzepatide for weight loss. @CBSEveningNews #Mounjaro #obesity #weightlossjourney #weightloss
cbsnews.com
Number 1 Top Cardiometabolic Story of 2023:
Triple GIP-GLP-1-GCG receptor agonist #retatrutide with stunning 24.2% average weight loss after 48 weeks in a phase 2 trial. @EliLillyandCo moves to phase. @AniaJastreboff
nejm.org
Triple GIP-GLP-1-GCG receptor agonist #retatrutide with stunning 24.2% average weight loss after 48 weeks in a phase 2 trial. @EliLillyandCo moves to phase. @AniaJastreboff
nejm.org
جاري تحميل الاقتراحات...